Dilmapimod Completed Phase 2 Trials for Acute Lung Injury (ALI) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00996840SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS